Protara Therapeutics, Inc. — Director's Dealing 2020

Jun 11, 2020

SEC Form 4/A — Form 4/A

Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2020-01-09

Reporting Person: GARCEAU ROGER (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-09	Stock Option (Right to Buy)	$9.18	A	12399	Acquired	2028-12-23	Common Stock (12399)	Direct

Footnotes

F1: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer.

F2: The Option Shares shall vest in forty eight (48) approximately equal increments of two hundred fifty eight (258) whole Option Shares beginning on the first day of the first calendar month following December 24, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a "Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then will vest and become exercisable.

F3: Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share.